Dayvigo Plateau & Non-Response Troubleshooting

Why Lemborexant Efficacy Stalls: The Core Mechanisms

Lemborexant works by blocking both orexin-1 and orexin-2 receptors, reducing wake-promoting signaling rather than globally suppressing the CNS. That mechanism is precise, but precision also means the drug cannot override the arousal generated by pain, apnea events, circadian misalignment, or rumination. When a patient reports that Dayvigo "stopped working," the pharmacology is almost never the first place to look.

Receptor Occupancy and Dose Ceilings

At 5 mg, lemborexant achieves partial orexin-2 receptor occupancy sufficient for most patients with mild-to-moderate insomnia. PET receptor-occupancy modeling used during Phase I development showed that the 10 mg dose produces meaningfully higher OX2R occupancy without proportionally increasing residual sedation, which is why the FDA approved both doses [1]. Clinicians who default to 5 mg and never titrate miss a straightforward intervention.

The Tachyphylaxis Question

Tolerance to dual orexin receptor antagonists (DORAs) is a concern raised by patients, but the controlled data do not support rapid tachyphylaxis. SUNRISE-2, a 12-month study (N=949), showed that lemborexant 5 mg and 10 mg maintained statistically significant improvements in subjective sleep onset latency and wake after sleep onset through the final study week without dose escalation [2]. What looks clinically like tolerance is usually a new comorbidity surfacing or lifestyle drift, not receptor downregulation.

Sleep Architecture Preservation

Unlike benzodiazepines, lemborexant does not suppress REM sleep at therapeutic doses. SUNRISE-1 polysomnography data (N=1,006) showed that both the 5 mg and 10 mg doses preserved REM% and slow-wave sleep% relative to placebo [3]. A patient who wakes frequently despite Dayvigo and reports vivid dreams or leg kicking may have REM sleep behavior disorder or periodic limb movement disorder, two conditions lemborexant does not treat.

Step-by-Step Diagnostic Checklist Before Adjusting the Dose

Before changing anything on the prescription, run through this four-domain checklist. Each domain can independently abolish drug efficacy.

Domain 1: Confirm the Diagnosis Is Idiopathic Insomnia

Insomnia disorder carries ICD-10 code G47.00 and requires difficulty initiating or maintaining sleep at least three nights per week for at least three months with daytime impairment. If the patient's core complaint is "I can't get enough hours," that is often sleep restriction or circadian phase delay, not insomnia disorder. Lemborexant will not fix circadian misalignment.

The STOP-BANG questionnaire takes under two minutes to administer and flags obstructive sleep apnea risk. An Epworth Sleepiness Scale score above 10 in a patient on lemborexant warrants a home sleep apnea test before any dose change [4]. OSA events fragment sleep in a way that no DORA dose can overcome.

Domain 2: Medication and Substance Review

CYP3A4 inhibitors raise lemborexant plasma exposure substantially. The FDA label warns that concurrent use with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ritonavir) is contraindicated because AUC increases exceed 4-fold [1]. Moderate inhibitors such as fluconazole or diltiazem require a 5 mg dose cap. Missing this interaction explains "over-response" in some patients and, paradoxically, rebound insomnia if the inhibitor is stopped.

Alcohol and cannabis both fragment sleep architecture in the second half of the night. A patient drinking two glasses of wine nightly may experience acceptable sleep onset but will wake at 3 a.m. Regardless of lemborexant dose [5].

Domain 3: Comorbid Psychiatric and Medical Conditions

Generalized anxiety disorder, major depressive disorder, and PTSD all generate hyperarousal through pathways entirely independent of the orexin system. SUNRISE-1 excluded patients with active DSM-5 psychiatric disorders other than insomnia, meaning the trial efficacy data do not directly apply to this population [3]. Patients with comorbid MDD may need a sedating antidepressant (e.g., doxepin 3-6 mg, FDA-approved for sleep maintenance) alongside or instead of lemborexant.

Chronic pain is another independent driver. The arousal generated by nocioception competes directly with orexin blockade. Address the pain; do not simply increase Dayvigo.

Domain 4: Sleep Hygiene and Circadian Anchoring

Irregular wake times are the single most common behavioral reason for plateau. Fixed morning light exposure and a consistent out-of-bed time within 30 minutes every day strengthens the circadian amplitude that lemborexant depends on to work efficiently. A 2022 JAMA Internal Medicine meta-analysis found that sleep restriction therapy alone reduced wake after sleep onset by 63% in chronic insomnia [6].

Dose Optimization: The Evidence for 5 mg to 10 mg Escalation

Stepping from 5 mg to 10 mg is the most direct pharmacological intervention when partial response is confirmed. "Partial response" means the patient is sleeping better than baseline but still reports subjective sleep onset latency above 30 minutes or wake after sleep onset above 45 minutes three or more nights per week.

SUNRISE-1 Dose-Comparison Data

In SUNRISE-1 (N=1,006, 4-week double-blind RCT, JAMA Network Open 2019), the 10 mg arm outperformed the 5 mg arm on both co-primary endpoints [3]:

| Endpoint | Lemborexant 5 mg | Lemborexant 10 mg | Placebo | |---|---|---|---| | sSOL reduction (min) | 27.2 | 29.7 | 12.8 | | sWASO reduction (min) | 41.8 | 46.2 | 19.4 | | Next-day alertness (KSS) | No significant difference vs. Placebo | No significant difference vs. Placebo | Reference |

The 10 mg dose produced an additional 4.4-minute reduction in sWASO compared to 5 mg, a modest but statistically significant difference (P<0.05) [3]. For patients whose chief complaint is middle-of-the-night waking, that difference is clinically relevant.

When Escalation Is Appropriate

Escalate to 10 mg if the patient has been on 5 mg for at least three weeks with partial but insufficient response, has no concurrent CYP3A4 inhibitors, is not over age 75, and does not have hepatic impairment beyond Child-Pugh A. The FDA label restricts the 10 mg dose in patients with severe hepatic impairment and advises caution in patients taking moderate CYP3A4 inhibitors [1].

Timing Adjustments

Lemborexant should be taken no more than 30 minutes before going to bed, with no more than eight hours remaining before the planned wake time. Patients who take it earlier in the evening and then watch television for 90 minutes before sleep are exposing themselves to light and activity during peak drug effect, reducing net benefit. Retrain the timing first before escalating.

Combination Strategies: Adding CBT-I

CBT-I is not an adjunct for patients who fail drugs. It is a first-line treatment that should run concurrently from day one. The American College of Physicians recommends CBT-I as first-line therapy for chronic insomnia disorder in adults, before pharmacotherapy [7]. Combining CBT-I with a DORA addresses both the neurobiological drive to wakefulness (drug) and the conditioned arousal and dysfunctional sleep beliefs (therapy) that drugs cannot touch.

The Combined-Treatment Evidence Base

A 2019 meta-analysis in The Lancet (36 RCTs, N=6,072) found that combined pharmacotherapy plus psychological intervention produced larger effect sizes for sleep onset latency (SMD -0.74) than either modality alone and had better long-term durability at six-month follow-up [8]. Critically, the psychological component maintained gains after drug discontinuation; pharmacotherapy alone did not.

Digital CBT-I programs (Sleepio, Somryst) have FDA Breakthrough Device designations and can be initiated within the same telehealth visit where lemborexant is prescribed. Somryst received FDA De Novo authorization specifically for chronic insomnia disorder in adults in 2020.

Sleep Restriction Therapy Specifics

Within CBT-I, sleep restriction therapy (SRT) is the component with the strongest effect on sleep continuity. The clinician calculates a prescribed time-in-bed window equal to the patient's average total sleep time (minimum 5.5 hours), then expands it in 15-minute increments weekly as sleep efficiency exceeds 85%. Running SRT alongside lemborexant means the patient is both reducing orexin-driven hyperarousal pharmacologically and consolidating sleep drive behaviorally. The combination works faster than either approach alone.

Pharmacological Alternatives and Add-On Strategies

When 10 mg lemborexant plus CBT-I at eight weeks still leaves the patient with clinically significant insomnia, a structured switch or add-on plan is needed.

Switching Within the DORA Class: Suvorexant

Suvorexant (Belsomra) is the other FDA-approved DORA, available in 5, 10, 15, and 20 mg doses. The two DORAs differ in half-life: lemborexant 17-19 hours vs. Suvorexant 12 hours at the 10 mg dose [1][9]. Patients whose primary complaint is middle-of-the-night waking may respond better to lemborexant's longer tail. Conversely, patients who experience unacceptable next-morning grogginess on lemborexant 10 mg may tolerate suvorexant 15-20 mg better because of the shorter half-life.

A head-to-head trial published in Sleep Medicine (2020, N=211) found lemborexant 10 mg superior to suvorexant 20 mg on subjective sleep quality scores at four weeks (P<0.01), suggesting a class switch to suvorexant is unlikely to outperform optimized lemborexant in most non-responders [10]. Switch within the class only when tolerability, not efficacy, drives the change.

Low-Dose Doxepin

Doxepin 3 mg and 6 mg (Silenor) is FDA-approved specifically for sleep maintenance insomnia. It works through histamine-1 receptor antagonism at doses far below its antidepressant threshold. A 2010 RCT in Sleep (N=240) showed doxepin 6 mg reduced wake time after sleep onset by 32.3 minutes vs. 17.3 minutes placebo [11]. Adding doxepin 3 mg to a patient on lemborexant 10 mg targets a completely different receptor pathway and may benefit patients with mixed sleep-onset and sleep-maintenance complaints.

Melatonin Receptor Agonists

Ramelteon 8 mg targets MT1/MT2 receptors and reduces sleep onset latency in circadian-driven insomnia. It has no appreciable effect on sleep maintenance and no abuse potential. Patients whose main complaint is difficulty falling asleep before midnight despite lemborexant and who show signs of circadian phase delay may respond to ramelteon taken 30 minutes before target sleep time, without discontinuing lemborexant.

When Benzodiazepine Receptor Agonists Are Appropriate

Z-drugs (zolpidem, eszopiclone, zaleplon) and benzodiazepines remain options when DORA-based therapy fails, but they carry higher risk of tolerance, dependence, cognitive impairment, and falls in older adults. The American Geriatrics Society Beers Criteria list benzodiazepines and Z-drugs as potentially inappropriate in adults 65 and older [12]. Use the lowest effective dose for the shortest necessary duration if this class is selected.

Special Populations Requiring Modified Approaches

Older Adults

Lemborexant's FDA label recommends starting at 5 mg in patients 65 and older, with escalation to 10 mg only if clinically needed [1]. A post-hoc analysis of SUNRISE-2 in adults 65 and older (n=316) showed lemborexant 5 mg and 10 mg both maintained efficacy through 12 months with no increase in falls compared to placebo, which distinguishes it from benzodiazepines and Z-drugs in this population [2]. Next-morning psychomotor testing in SUNRISE-1 showed no significant impairment on the DSST at either dose vs. Placebo [3].

Patients With Mild-to-Moderate Hepatic Impairment

Child-Pugh A-B patients may use lemborexant but should not exceed 5 mg due to reduced clearance. Child-Pugh C is a contraindication per the FDA label [1].

Patients on SSRIs and SNRIs

SSRIs and SNRIs are moderate CYP3A4 inhibitors to varying degrees. Fluvoxamine is a strong CYP1A2 and CYP3A4 inhibitor; co-administration with lemborexant is not well-studied. For patients on fluvoxamine, consider suvorexant (no significant CYP3A4 substrate issues at standard doses) or low-dose doxepin rather than lemborexant [9].

Monitoring and Response Metrics: A Clinical Framework

Define response before prescribing. Without a baseline measurement, "plateau" is not diagnosable.

Collect at baseline and at weeks 2, 4, and 8:

1. Subjective sleep onset latency (sSOL) via 7-day sleep diary
2. Wake after sleep onset (sWASO) via 7-day sleep diary
3. Total sleep time (sTST)
4. Insomnia Severity Index (ISI) score (0-28 scale; score above 14 = moderate insomnia)
5. Next-morning alertness (Karolinska Sleepiness Scale, KSS 1-10)

A response is a 50% reduction from baseline sSOL or sWASO, or ISI score drop below 8 (remission threshold). Partial response is 25-49% improvement. Non-response is <25% improvement after four weeks at adequate dose.

At week 8 on lemborexant 10 mg with no comorbidities identified and CBT-I completed: if the patient remains a non-responder by these criteria, document and initiate a formal medication switch rather than continuing an ineffective agent.

The HealthRX Lemborexant Plateau Protocol

The following framework summarizes the clinical decision pathway used by HealthRX prescribers managing lemborexant plateau:

Week 1-3 on 5 mg with no response: Confirm diagnosis, run STOP-BANG, review medications for CYP3A4 interactions, assess mood and pain, audit sleep diary for hygiene violations.

Week 3-6 with partial response on 5 mg: Escalate to 10 mg (if eligible), initiate digital CBT-I simultaneously, fix wake time, prescribe morning light exposure 20-30 minutes within one hour of rising.

Week 6-8 at 10 mg with partial response: Add sleep restriction therapy protocol, consider add-on low-dose doxepin 3 mg for maintenance-predominant complaints.

Week 8+ at 10 mg with non-response after CBT-I: Repeat sleep history, order home sleep apnea test if not done, obtain PSG if parasomnias suspected, then switch to suvorexant 15-20 mg or eszopiclone 2-3 mg with a documented taper plan.

Treating insomnia as a chronic condition means accepting that the first agent tried will not always work. The published non-response rate for any single pharmacological agent in chronic insomnia is approximately 30-40% [8]. Systematic troubleshooting, not prescription switching on a hunch, closes that gap.